Orthopedic kickbacks
This article was originally published in The Gray Sheet
Executive Summary
The Jan. 14, 2008 issue (1back page) erroneously reported that Arkansas surgeon Patrick Chan pled guilty Jan. 3 to receiving illegal kickbacks from Synthes and Blackstone Medical (now part of Orthofix). In fact, Chan pled guilty to receiving illegal kickbacks from a distributor of spine surgery devices made by Osteotech, Orthofix, Alphatec and Signus. Chan's agreement to pay $1.5 million to settle a whistleblower's allegations that he took illegal kickbacks from Synthes and Blackstone is part of a separate civil case, in which he admitted no wrongdoing
You may also be interested in...
Orthofix/Blackstone kickback case
Arkansas surgeon Patrick Chan pleads guilty Jan. 3 to receiving illegal kickbacks from orthopedic device-makers Synthes and Blackstone Medical, which was acquired by Orthofix in 2006 (1"The Gray Sheet" Aug. 6, 2007, In Brief). Chan has also entered into a $1.5 million civil settlement with the U.S. government, the State of Arkansas and the "whistle-blower," an orthopedic device salesman who brought the case, in which Blackstone and Synthes are co-defendants, to the government's attention in 2006. Because Chan is expected to leave the country once sentenced, the prosecuting attorney filed a petition with the court Jan. 7 to first subpoena and depose him, since "Chan still has critical evidence on his remaining co-defendants' scheme to induce Chan and other surgeons to use the defendants' surgical products by paying them kickbacks under the guise of consulting agreements and similar arrangements.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.